4.37

19.40% 0.71

After Hours: 4.35 -0.02 -0.46%

C 4 Therapeutics Inc (CCCC)

Overview News Price History Option Chain Financials Discussions Forecast

C 4 Therapeutics Inc stock is traded at $4.37, with a volume of 5.89M. It is up +19.40% in the last 24 hours and up +70.70% over the past month. C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.

Previous Close:

$3.66

Open:

$3.66

24h Volume:

5.89M

Relative Volume:

1.94

Market Cap:

$483.18M

Revenue:

$35.95M

Net Income/Loss:

$-104.99M

P/E Ratio:

-3.2211

EPS:

-1.3567

Net Cash Flow:

$-99.30M

1W Performance:

+22.75%

1M Performance:

+70.70%

6M Performance:

+61.25%

1Y Performance:

+231.06%

1-Day Range:

$3.66

$4.575

1-Week Range:

$3.475

$4.575

52-Week Range:

$1.21

$4.575

C 4 Therapeutics Inc Stock (CCCC) Company Profile

Name

C 4 Therapeutics Inc

Sector

Healthcare (1108)

Industry

Biotechnology (618)

Phone

(617) 231-0700

Address

490 ARSENAL WAY, WATERTOWN

Employee

104

Twitter

Next Earnings Date

2026-05-13

Latest SEC Filings

CCCC's Discussions on Twitter

Compare CCCC vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CCCC C 4 Therapeutics Inc	4.37	404.68M	35.95M	-104.99M	-99.30M	-1.3567
VRTX Vertex Pharmaceuticals Inc	447.54	113.70B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	614.78	65.16B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	835.99	52.14B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	301.98	40.73B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	157.48	32.87B	742.00K	-1.37B	-1.07B	-7.0731

C 4 Therapeutics Inc Stock (CCCC) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-02-25	Initiated	TD Cowen	Buy
Sep-17-25	Initiated	Barclays	Overweight
Sep-15-25	Upgrade	Stephens	Equal-Weight → Overweight
Sep-04-25	Initiated	Guggenheim	Buy
Dec-19-24	Upgrade	Wells Fargo	Equal Weight → Overweight
Nov-18-24	Initiated	Stephens	Equal-Weight
Jan-29-24	Upgrade	JP Morgan	Underweight → Neutral
Dec-13-23	Upgrade	Stifel	Hold → Buy
Feb-24-23	Upgrade	Credit Suisse	Underperform → Neutral
Feb-24-23	Downgrade	JP Morgan	Neutral → Underweight
Nov-04-22	Downgrade	JP Morgan	Overweight → Neutral
Oct-11-22	Initiated	Morgan Stanley	Underweight
Apr-28-22	Initiated	Credit Suisse	Underperform
Apr-11-22	Downgrade	BofA Securities	Buy → Neutral
Mar-10-22	Initiated	JP Morgan	Overweight
Feb-11-22	Resumed	BMO Capital Markets	Outperform
Feb-10-22	Initiated	Wells Fargo	Equal Weight
Nov-23-21	Initiated	BofA Securities	Buy
Oct-14-21	Initiated	SVB Leerink	Mkt Perform
Sep-30-21	Initiated	Stifel	Hold
Jun-04-21	Initiated	H.C. Wainwright	Buy
Mar-31-21	Initiated	BMO Capital Markets	Outperform
Oct-28-20	Initiated	UBS	Buy
Oct-27-20	Initiated	BMO Capital Markets	Outperform
Oct-27-20	Initiated	Jefferies	Buy

View All

C 4 Therapeutics Inc Stock (CCCC) Latest News

04:30 AM

Biotech Zevra hands new hires 33,000 stock options in grants - Stock Titan

04:30 AM

04:20 AM

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

04:20 AM

03:08 AM

C4 Therapeutics (CCCC) Hits 52-Week High Following BMY Trial Success - GuruFocus

03:08 AM

May 28, 2026

CCCC (NASDAQ) insider exercise-and-sale: 9,087 options sold from 29,080 grant - Stock Titan

May 28, 2026

May 25, 2026

Are medical stocks lagging C4 Therapeutics (CCCC) this year? - MSN

May 25, 2026

May 22, 2026

Avalo Therapeutics Announces Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance

May 22, 2026

May 21, 2026

CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

May 21, 2026

May 20, 2026

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Caledonian Record

May 20, 2026

Clinical trial participation drives development of innovative treatments, C4 Therapeutics, Inc. - Traders Union

May 20, 2026

C4 Therapeutics to Participate in Upcoming Conferences - Investing News Network

May 20, 2026

C4 Therapeutics to speak at TD Cowen, Jefferies, Goldman healthcare events - Stock Titan

May 20, 2026

May 19, 2026

C4 Therapeutics deepens Roche alliance to target breakthrough cancer therapies - MSN

May 19, 2026

C4 Therapeutics (NASDAQ: CCCC) — Squadron Fund reports 5.55M shares - Stock Titan

May 19, 2026

May 18, 2026

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Globe and Mail

May 18, 2026

C4 Therapeutics, Inc. to present new cemsidomide Phase 1 data at EHA Hematology 2026 Congress - Traders Union

May 18, 2026

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Business Wire

May 18, 2026

May 16, 2026

C4 Therapeutics Realigns Finance Leadership After Officer Departure - The Globe and Mail

May 16, 2026

May 15, 2026

Acrivon Therapeutics announces inducement grant under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com

May 15, 2026

Point72 reports 169,096-share stake in C4 Therapeutics (CCCC) as of Mar 31, 2026 - Stock Titan

May 15, 2026

Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

May 15, 2026

C4 Therapeutics (NASDAQ: CCCC) names CFO as principal accountant - Stock Titan

May 15, 2026

Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

May 15, 2026

Are Medical Stocks Lagging C4 Therapeutics (CCCC) This Year? - Yahoo Finance

May 15, 2026

C4 Therapeutics, Inc. (NASDAQ:CCCC) Just Reported And Analysts Have Been Lifting Their Price Targets - simplywall.st

May 15, 2026

C4 Therapeutics (CCCC) — Sirenia/Silverstein report 23.5M shares, near 10% stake - Stock Titan

May 15, 2026

C4 Therapeutics, Inc.Common Stock (NQ: CCCC - FinancialContent

May 15, 2026

May 14, 2026

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire

May 14, 2026

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance

May 14, 2026

May 13, 2026

Bicara Therapeutics announces inducement grant under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com

May 13, 2026

Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

May 13, 2026

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 12, 2026 - BioSpace

May 13, 2026

May 12, 2026

BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

May 12, 2026

Biogen Inc. stock (US09062X1037): Q1 milestone payment amid partner C4 Therapeutics earnings - AD HOC NEWS

May 12, 2026

C4 Therapeutics (CCCC) Reports Strong Q1 Revenue and Clinical Ad - GuruFocus

May 12, 2026